Another molecular alteration commonly treated with targeted therapies is rearrangement in the anaplastic lymphoma kinase gene (ALK), which is diagnosed in approximately 5–7% of NSCLC patients, mostly young individuals with the signet-ring-cell subtype of lung adenocarcinoma [13]. The gene discussed is ALK; the disease is non-small cell lung carcinoma.